Making and Separating Specific Chemical Forms of a Drug Compound
This patent describes a method to convert a specific chemical compound into a balanced mixture of its mirror-image forms and then separate one desired form, important for making medicines.
Original patent title: “Process for racemizing and isolating atropisomers of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione”
This patent describes a method to convert a specific chemical compound into a balanced mixture of its mirror-image forms and then separate one desired form, important for making medicines. Granted in 2026.
Coverage
What does this patent actually cover?
This patent provides a method for making and separating specific chemical forms of a complex molecule referred to as 'Compound A' (7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione). One process involves heating a composition containing the (P)-form of Compound A, or its salt, with a solvent to a high temperature, specifically between 250° C. and 350° C. This heating step converts the pure (P)-form into a mixture of both mirror-image forms, known as racemized Compound A. Additionally, the patent describes a process for isolating the desired (P)-Compound A from a mixture that includes a tartrate, which helps in the separation. It also details a method for isolating the free acid of a tartrate or its hydrate from a composition containing the tartrate, (P)-Compound A, and an organic solvent. For example, a pharmaceutical company could use this process to ensure a drug contains only the effective (P)-Compound A, avoiding the inactive or harmful mirror-image form.
The gap
What does this patent NOT cover?
- Does not cover racemization processes for chemical compounds other than 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione.
- Does not cover racemization of (P)-compound A at temperatures outside the specified range of 250° C. to 350° C.
- Does not cover isolation methods for (P)-compound A that do not involve the use of a tartrate.
- Does not cover separation of other types of isomers, such as enantiomers that are not atropisomers, or diastereomers.
- Does not cover processes for isolating (P)-compound A from compositions that do not contain a tartrate.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → likely lies in discovering the precise high-temperature conditions (250-350°C) required to efficiently convert a specific atropisomer into a racemic mixture, and then a specific method using tartrates to isolate the desired pure form of Compound A.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Pharmaceutical manufacturing of specific drug components
High-temperature chemical synthesis processes for chiral molecules
Why it matters
The bigger picture
In drug development, often only one specific mirror-image form of a molecule, called an atropisomer, has the desired therapeutic effect while the other form might be inactive or even harmful. This patent provides methods to ensure that the correct form of a specific compound, 'Compound A', is produced and separated efficiently for pharmaceutical use. This precision is critical for drug safety and effectiveness.
Filed
October 6, 2021
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Pharmaceutical companies and contract manufacturing organizations (CMOs) involved in the synthesis of complex drug molecules, particularly those requiring precise control over molecular handedness, would be interested in or building upon such processes. Companies like Pfizer, Novartis, or Merck, which develop and produce small-molecule drugs, could utilize similar chemical methods to ensure the purity and efficacy of their products.
Market impact
If 'Compound A' is a key ingredient in a commercial drug, this patent provides a crucial manufacturing advantage by offering a specific, efficient method for producing the desired pure form. This could reduce production costs, improve drug purity, and potentially block competitors from using this exact process to make the same active pharmaceutical ingredient, thereby securing market share for the drug's developer.
Claim 1 — Plain English
What this patent covers
This patent provides a method for making and separating specific chemical forms of a complex molecule referred to as 'Compound A' (7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione). One process involves heating a composition containing the (P)-form of Compound A, or its salt, with a solvent to a high temperature, specifically between 250° C. and 350° C. This heating step converts the pure (P)-form into a mixture of both mirror-image forms, known as racemized Compound A. Additionally, the patent describes a process for isolating the desired (P)-Compound A from a mixture that includes a tartrate, which helps in the separation. It also details a method for isolating the free acid of a tartrate or its hydrate from a composition containing the tartrate, (P)-Compound A, and an organic solvent. For example, a pharmaceutical company could use this process to ensure a drug contains only the effective (P)-Compound A, avoiding the inactive or harmful mirror-image form.
The clever bit
The novelty likely lies in discovering the precise high-temperature conditions (250-350°C) required to efficiently convert a specific atropisomer into a racemic mixture, and then a specific method using tartrates to isolate the desired pure form of Compound A.
What it does not cover
- Does not cover racemization processes for chemical compounds other than 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione.
- Does not cover racemization of (P)-compound A at temperatures outside the specified range of 250° C. to 350° C.
- Does not cover isolation methods for (P)-compound A that do not involve the use of a tartrate.
- Does not cover separation of other types of isomers, such as enantiomers that are not atropisomers, or diastereomers.
- Does not cover processes for isolating (P)-compound A from compositions that do not contain a tartrate.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 15.0 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). Making and Separating Specific Chemical Forms of a Drug Compound (U.S. Patent No. 12,735,419). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12735419/process-for-racemizing-and-isolating-atropisomers-of
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12735419"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Making and Separating Specific Chemical Forms of a Drug Compound cover?
This patent describes a method to convert a specific chemical compound into a balanced mixture of its mirror-image forms and then separate one desired form, important for making medicines.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
In drug development, often only one specific mirror-image form of a molecule, called an atropisomer, has the desired therapeutic effect while the other form might be inactive or even harmful. This patent provides methods to ensure that the correct form of a specific compound, 'Compound A', is produced and separated efficiently for pharmaceutical use. This precision is critical for drug safety and effectiveness.
What does this patent NOT cover?
Does not cover racemization processes for chemical compounds other than 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione.
Patent monitoring